Investor Presentation - First Six Months of 2021

70 Investor presentation First six months of 2021 Biopharm sales growth of 7% driven by solid commercial execution with key brands being EsperoctⓇ and Refixia® NovoSevenⓇ and NorditropinⓇ account for ~80% of Biopharm sales DKK billion 25 -16% -1% 4% 1% 7% 20 Added sales within rare blood disorders DKK billion 15 10 5 0 2017 NovoSeven Norditropin 5.2 5.4 2018 2019 2020 YTD 2021 H1 Haemophilia Haemophilia NovosevenⓇ 2020 A B H1 2021 1 Other haemophilia products Other biopharm Growth at CER Note: Company reported sales; CER: Constant exchange rates; 1Other haemophilia products primarily consists of VagifemⓇ and ActivelleⓇ Novo NordiskⓇ

View entire presentation